GlassScriptPhysician profile
Megan Sanford
NPI 1073002515
$4,075.99
in general payments reported to CMS, 2019-2025
38 companies · $815 in 2025
The $815 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $172 · 2022: $913 · 2023: $1,033 · 2024: $1,143 · 2025: $815.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,930 · Education: $61.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,930.28 |
| Education | $61.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,014.64 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $478.95 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $421.75 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $269.91 | 2021-2025 | |
| Pfizer INC. | $181.27 | 2022-2025 | |
| Dexcom, INC. | $159.93 | 2023-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $155.26 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Exact Sciences Corporation | $109.05 | 2023-2024 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $105.71 | 2021-2025 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.73 | 2022-2025 | Xifaxan |
| Amarin Pharma, INC. | $98.94 | 2021-2022 | |
| Astellas Pharma US INC | $90.95 | 2023-2024 | Veozah |
| Amgen INC. | $87.19 | 2022-2025 | Otezla, Repatha, Repatha |
| Phathom Pharmaceuticals, INC. | $84.98 | 2024-2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $75.42 | 2023-2025 | Rexulti |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Sanford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.